https://www.nytimes.com/2022/10/14/opinion/experim
Post# of 148112
(Total Views: 590)
Posted On: 10/15/2022 8:15:11 AM
https://www.nytimes.com/2022/10/14/opinion/ex...tment.html
Excerpt:
In response, the Food and Drug Administration has created programs that speed up access to new medical products for serious conditions that lack effective treatments.
The agency recently approved a treatment for A.L.S., a fatal neurological disorder, despite questions about whether the drug, called Relyvrio, will extend patients’ lives or slow the progression of their disease. Because the drug appears safe, the agency reasoned that “given the serious and life-threatening nature of A.L.S. and the substantial unmet need, this level of uncertainty is acceptable in this instance.”
https://www.nytimes.com/2022/10/14/opinion/ex...tment.html
Excerpt:
In response, the Food and Drug Administration has created programs that speed up access to new medical products for serious conditions that lack effective treatments.
The agency recently approved a treatment for A.L.S., a fatal neurological disorder, despite questions about whether the drug, called Relyvrio, will extend patients’ lives or slow the progression of their disease. Because the drug appears safe, the agency reasoned that “given the serious and life-threatening nature of A.L.S. and the substantial unmet need, this level of uncertainty is acceptable in this instance.”
https://www.nytimes.com/2022/10/14/opinion/ex...tment.html
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼